Catalan Institute of Oncology (ICO)

Despite considerable advances in the discovery and development of new cancer drugs, there are significant disparities in both the availability and timeliness of these medicines around the world, with the poorest countries being left out, according to an analysis published in the journal BMJ Global Health. According to the study, few new cancer drugs were launched in low- and lower-middle-income countries, and the gap between rich and poor countries widened over the three decades between 1990 and 2022.

Prostate cancer screening tests using PSA (Prostate Specific Antigen) are associated with overdiagnosis, which calls into question their use. A clinical trial in men aged 50-60 years published in the journal NEJM has studied the possibility of adding an MRI test in those with an elevated PSA level and dispensing with biopsy if imaging finds no suspicious lesions. The results indicate that the procedure avoids more than half of clinically irrelevant cancer diagnoses that would not need treatment and only slightly increases the risk of failing to identify those that may become incurable. The authors recommend, on the basis of the study, to review the recommendations for such screening.

A study has analyzed data on prostate cancer incidence and mortality in 26 countries in Europe between 1980 and 2020. Its findings are that new diagnoses have increased due to the widespread use of PSA [prostate-specific antigen] testing, but mortality rates have not benefited in parallel. This suggests possible overdiagnosis, i.e., the detection of harmless tumors that are unlikely to cause symptoms or death in the patient's lifetime. The results are published in the journal The BMJ. 

The sperm of men infected with high-risk genotypes of the human papillomavirus (HPV) suffers more damage from oxidative stress and has a weaker immune response, which can lead to reduced fertility. This is one of the conclusions of a study published in the journal Frontiers in Cellular and Infection Microbiology. The research compared the semen of 20 adults infected with high-risk genotypes, seven infected with low-risk genotypes, and 43 adults without infections.

Research led by the Hospital del Mar Research Institute (Barcelona) and involving researchers from CIMA (University of Navarra) and Pompeu Fabra University (Barcelona) has revealed the existence of microproteins present almost exclusively in hepatocellular carcinoma, the most common form of liver cancer. These structures, which appear to be found in a significant percentage of patients, could be used to develop specific vaccines against this type of tumour. The results are published in the journal Science Advances.

A clinical trial in Finland has compared the effectiveness of nicotine-containing e-cigarettes and varenicline tablets for smoking cessation. The study, which included 458 participants, found no difference between the two strategies at six months. However, after one year, only varenicline was found to be clearly more effective than placebo. The results are published in the journal JAMA Internal Medicine.  

The classical view describes most cancers as the result of mutations that happen by chance and accumulate over a lifetime. Now, a study claims to break that paradigm. A team of researchers from Stanford University (USA) has described that the genetics we inherit influences the surveillance that our defences do of these mutations, conditioning the type of tumour that can develop and its prognosis. The results, which for the moment refer to breast cancer, are published in the journal Science.  

This Friday, the Interterritorial Council of the National Health System approved the Comprehensive Plan for the Prevention and Control of Smoking (PIT). The document, which incorporates 147 proposals from the autonomous communities, has not achieved consensus among all of them.
 

By 2050, there will be more than 35 million new cases of cancer worldwide, an increase of 77% from the 20 million cases reported in 2022. These are projections made by the WHO's International Agency for Research on Cancer (IARC), which has published the latest estimates of the global burden of cancer. Using data from 185 countries, IARC estimates that in 2022 lung cancer was the most common cancer worldwide, with female breast cancer in second place, followed by colorectal, prostate and stomach cancer. The authors stress the urgent need to address inequalities around these diseases.

International research estimates that by 2024 there will be approximately 1,270,800 deaths from different types of cancer in the European Union (EU) as a whole. In the specific case of colorectal cancer, the researchers estimate that mortality rates will increase among people aged between 25 and 49 in the EU. In Spain, the increase will be 5.5 % in men. The authors of the research, published in the Annals of Oncology, attribute this increased mortality to overweight, obesity and alcohol consumption in this age group.